

MEDICAL ASSISTANCE HANDBOOK
PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES

I. Requirements for Prior Authorization of Analgesics, Narcotic Long Acting

A. Prescriptions That Require Prior Authorization

Prescriptions for Analgesics, Narcotic Long Acting that meet any of the following conditions must be prior authorized:

1. A prescription for a non-preferred Analgesic, Narcotic Long Acting regardless of the quantity prescribed. See Preferred Drug List (PDL) for the list of preferred Analgesic, Narcotic Long Acting at:
http://www.providersynergies.com/services/documents/PAM_PDL_20101115.pdf
2. A prescription for a preferred Analgesic, Narcotic Long Acting with a prescribed quantity that exceeds the quantity limit. See Quantity Limits for the list of drugs with quantity limits at:
http://www.dpw.state.pa.us/ucmprd/groups/webcontent/documents/document/s_002077.pdf
3. A prescription for either a preferred or non-preferred Analgesic, Narcotic Long Acting when the recipient is taking more than one Analgesic, Narcotic Long Acting concurrently.

The PROMISe Point-Of-Sale On-Line Claims Adjudication System will verify if the recipient has a record of a prescription for an Analgesic, Narcotic Long Acting within the past 60 days.

4. A prescription for either a preferred or non-preferred Analgesic, Narcotic Long Acting when a recipient has a concurrent prescription for an Oral Buprenorphine Agent.
5. A prescription for either a preferred or non-preferred Analgesic, Narcotic Long Acting when there is a record of 4 or more paid claims for Analgesics, Narcotic Long Acting and Analgesics, Narcotic Short Acting in PROMISe, the Department's Point-of-Sale On-Line Claims Adjudication System within the past 30 days.
6. A prescription for either a preferred or non-preferred Analgesic, Narcotic Long Acting when prescribed for a child under 21 years of age.

MEDICAL ASSISTANCE HANDBOOK
PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES

B. Clinical Review Guidelines and Review of Documentation for Medical Necessity

In evaluating a request for prior authorization of a prescription for an Analgesic, Narcotic Long Acting, the determination of whether the requested prescription is medically necessary will take into account the following:

1. For all non-preferred Analgesics, Narcotic Long Acting – Whether the recipient:
 - a. Has a history of intolerance, a contraindication to, or therapeutic failure of preferred Analgesic, Narcotic Long Acting drugs.

AND

- b. Is prescribed an FDA-approved starting dose or there is documentation demonstrating an appropriate upward titration or an appropriate conversion from other opioid containing medications.
2. For a prescription for either a preferred or non-preferred Analgesic, Narcotic Long Acting when there is a record of 4 or more paid claims for Analgesics, Narcotic Long Acting and Analgesics, Narcotic Short Acting, whether:
 - a. The multiple prescriptions are consistent with medically accepted prescribing practices and standards of care, including support from peer-reviewed literature or national treatment guidelines that corroborate use of the quantity of medication being prescribed

AND

- b. The multiple prescriptions are written by the same prescriber or, if written by different prescribers, all prescribers are aware of the other prescription(s)
3. For a prescription for either a preferred or non-preferred Analgesic, Narcotic Long Acting when prescribed for a child under 21 years of age, whether the recipient:
 - a. Has documentation of pain that is:

MEDICAL ASSISTANCE HANDBOOK
PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES

- i. Caused by a medical condition

AND

- ii. Not neuropathic or migraine in type

AND

- iii. Severe, as documented by a pain assessment tool measurement (e.g., a numeric or visual analog scale)

AND

- b. Has documentation of the anticipated duration of therapy

AND

- c. Has documentation of therapeutic failure, contraindication or intolerance to the following pain management modalities:

- i. Non-pharmacologic techniques (i.e., behavioral, cognitive, physical and/or supportive therapies)

AND

- ii. Non-opioid analgesics (e.g., acetaminophen, NSAIDs)

AND

- d. Is prescribed a dose that is appropriate for the recipient's age and/or weight, as listed in:

- i. The FDA-approved package insert

OR

- ii. Nationally recognized compendia for medically-accepted indications for off-label use

OR

MEDICAL ASSISTANCE HANDBOOK
PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES

- iii. Medically accepted standards of care that corroborate use, such as peer-reviewed literature or national treatment guidelines

AND

- e. Has documentation that the recipient or parent/guardian has been educated on the potential adverse effects of opioid analgesics, including the risk for misuse, abuse and addiction

AND

- f. Was assessed for recent use (within the past 60 days) of an opioid analgesic

AND

- g. For a recipient with a history of substance use disorder, has a recent urine drug screen (including testing for licit and illicit drugs with the potential for abuse; must include specific testing for oxycodone and fentanyl) that is consistent with prescribed controlled substances

OR

- 4. For all Analgesic, Narcotic Long Acting drugs that do not meet the clinical review guidelines listed above, in the professional judgment of the physician reviewer, the services are medically necessary to meet the medical needs of the recipient.
- 5. When determining medical necessity of a prescription for a preferred or non-preferred Analgesic, Narcotic Long Acting for a recipient with a concurrent prescription for an Oral Buprenorphine Agent, the physician reviewer will consider whether:
 - a. The prescription for the Oral Buprenorphine Agent and the Analgesic, Narcotic Long Acting are written by the same prescriber or, if written by different prescribers, all prescribers are aware of the other prescription(s)

AND

MEDICAL ASSISTANCE HANDBOOK
PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES

- b. The recipient has a need for therapy with an Analgesic, Narcotic Long Acting and the Oral Buprenorphine therapy will be suspended during the treatment for pain

Quantity Limits - In addition, if the quantity of a prescription for either a preferred or non-preferred Analgesic, Narcotic Long Acting exceeds the quantity limit, the determination of whether the prescription is medically necessary will take into account the guidelines in the Quantity Limits Handbook Chapter and whether:

- 1. The recipient has moderate to severe pain

AND

- 2. The medication is being prescribed by an appropriate specialist or in consultation with an appropriate specialist

AND

- 3. A narcotic pain reliever at the requested dose is the most appropriate treatment option as documented by the following:

- a. Pain is inadequately controlled at the current quantity limit

AND

- b. Pain is inadequately controlled by other Analgesics, Narcotic Long Acting

OR

- c. The recipient has a history of a contraindication or adverse reaction to alternative Analgesics, Narcotic Long Acting

AND

- 4. For doses that exceed the FDA-approved starting dose, there is documentation demonstrating an appropriate upward titration or an appropriate conversion from other opioid-containing medications.

AND

MEDICAL ASSISTANCE HANDBOOK
PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES

5. The requested dosing interval does not exceed the maximum FDA-approved dosing interval.

OR

6. The quantity of a prescription for either a preferred or non-preferred Analgesic, Narcotic Long Acting exceeds the quantity limit and does not meet the guidelines listed above, but in the professional judgment of the physician reviewer, the services are medically necessary to meet the medical needs of the recipient.

C. Automated Prior Authorization

Prior authorization of a prescription for a preferred Analgesic, Narcotic Long Acting, for a recipient under 21 years of age, will be automatically approved when the PROMISe Point-of-Sale On-Line Claims Adjudication System verifies a record of a paid claim 365 days prior to the date of service that documents a diagnosis of cancer, sickle cell with crisis or newborn drug withdrawal syndrome.

D. Clinical Review Process

Prior authorization personnel will review the request for prior authorization and apply the clinical guidelines in Section B. above, to assess the medical necessity of the request for a prescription for an Analgesic, Narcotic Long Acting. If the guidelines in Section B. are met, the reviewer will prior authorize the prescription.

The prior authorization request will be referred to a physician reviewer for a medical necessity determination when any of the following occur:

1. The guidelines are not met

OR

2. The prescription is for a Analgesic, Narcotic Long Acting with a concurrent prescription for an Oral Buprenorphine Agent

Such a request for prior authorization will be approved when, in the professional judgment of the physician reviewer, the services are medically necessary to meet the medical needs of the recipient.

References:

MEDICAL ASSISTANCE HANDBOOK
PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES

1. Methadone: focus on safety. Pharmacist's Letter/Prescriber's Letter 2006; 22(9):220902
2. Cytochrome P450 drug interactions. Pharmacist's Letter/Prescriber's Letter 2006; 22(2):220233
3. Subutex [package insert]. South San Francisco, CA: Genentech, Inc.; September 2006
4. Suboxone [package insert]. South San Francisco, CA: Genentech, Inc.; September 2006
5. Suboxone/Subutex Pharmacist's Letter/Prescriber's Letter 2009;25(1):250101.
6. Hauer J, Jones BL. Evaluation and management of pain in children, UpToDate. Accessed August 12, 2013.
7. Wilford BB, Parran TV, DuPont RL. Prescription drug abuse and addiction: prevention, identification, and management, UpToDate. Accessed August 12, 2013.
8. Substance Abuse and Mental Health Services Administration, Results
9. National Institute on Drug Abuse, Topics in Brief: Prescription Drug Abuse, Revised December 2011
10. American News Report, Should Children Take Opioid Painkillers? July 10, 2012